Transfer of interferon β-1a into human breastmilk

Breastfeed Med. 2012 Apr;7(2):123-5. doi: 10.1089/bfm.2011.0044. Epub 2011 Oct 11.

Abstract

Aim: This study determined the transfer of intramuscular interferon β-1a into human milk and provides an estimate of infant exposure to this antiviral in six women chronically receiving intramuscular interferon β-1a (Avonex(®), Biogen Idec, Research Triangle Park, NC).

Methods: Interferon β-1a was measured at various times at steady state in milk samples collected from women receiving interferon β-1a at 30 μg/week.

Results: Average milk concentrations were 46.7, 97.4, 66.4, 77.5, 103.1, 108.3, 124, and 87.9 pg/mL at 0, 1, 4, 8, 12, 24, 48, and 72 hours, respectively, after dosing. Using the highest value measured (179 pg/mL), the estimated relative infant dose would be 0.006% of the maternal dose.

Conclusions: These data clearly suggest that interferon β-1a does not penetrate the milk compartment significantly and that levels in milk are far subclinical. No side effects were noted in any of the breastfed infants.

MeSH terms

  • Adjuvants, Immunologic / adverse effects
  • Adjuvants, Immunologic / pharmacokinetics*
  • Adult
  • Breast Feeding / adverse effects
  • Dose-Response Relationship, Drug
  • Female
  • Humans
  • Infant
  • Injections, Intramuscular
  • Interferon beta-1a
  • Interferon-beta / adverse effects
  • Interferon-beta / pharmacokinetics*
  • Lactation / metabolism*
  • Milk, Human / chemistry*
  • Multiple Sclerosis / drug therapy*

Substances

  • Adjuvants, Immunologic
  • Interferon-beta
  • Interferon beta-1a